Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabsA new daily pill could be a more effective GLP-1 tablet for weight

The second head-to-head Phase 3 trial in a week between dueling metabolic drugs from Eli Lilly and Novo Nordisk was reported Thursday. Once again, the data went Lilly’s way.

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to

More than 200 participants enrolled as company targets topline data by end of 2026

WEDNESDAY, Feb. 25, 2026 — Some of the most popular diabetes and weight-loss drugs in the U.S. will soon cost a lot less.
Novo Nordisk announced Tuesday that it

Reports of people developing scurvy while taking GLP-1 medications are on the rise. Milles Team/Shutterstock

Reports of GLP-1 users developing scurvy have increased in recent months.

GLP-1 drugs can lead

(MedPage Today) — DENVER — People with HIV didn’t have a significant rise in depressive symptoms after starting semaglutide (Ozempic, Wegovy, Rybelsus) for diabetes or weight loss, according to a

Novo Nordisk said that starting next year, it will lower the list price of its popular GLP-1 products to $675 per month in a cost-cutting effort focused on patients with

Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026 –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC),

(MedPage Today) — Some participants in a weight-loss trial of retatrutide, an investigational triple-hormone receptor agonist, dropped out because they thought they were losing too much weight. (New York Times)<br

Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as much as 50%, while boasting Phase 2 data for

Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.

The Trump administration released detailed guidance for approving the first bespoke medicines crafted to treat individual patient mutations

Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion

Audience: Health Care Professional, Consumer January 13, 2026

FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications
This

(MedPage Today) — Meals and snacks with “GLP-1 Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity drugs like

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the

Now that GLP-1 drugs have revolutionized how millions of Americans treat obesity and Type 2 diabetes, scientists are exploring the benefits of using the drugs for a host of other

Gordon Ramsay, celebrity chef, slams restaurants for creating Mounjaro-minded menus, calling the GLP-1-inspired dining trend “stupid” and “embarrassing.”

In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss

Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.

WEDNESDAY, Feb. 18, 2026 — The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online

(MedPage Today) — The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition and even the comeback of scurvy. (The Hill)
An $80-per-month produce

Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans think about weight loss. In fact, a recent poll finds 1 in 8 adults are

The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday

Medications for obesity may improve fertility, but there are many unknowns when it comes to using them during pregnancy.

FRIDAY, Feb. 20, 2026 — Satisfaction with semaglutide (Ozempic) is mainly driven by effective weight loss despite gastrointestinal side effects, according to a study published in the February issue of

FRIDAY, Feb. 20, 2026 — For patients with diabetes and overweight or obesity, tirzepatide use is associated with a lower incidence of new or progressive diabetic retinopathy (DR) and fewer

Could weight-loss drugs shrink the body representation we’ve spent decades seeking?

For the first time, researchers show that tirzepatide—the active ingredient in the diabetes and weight-loss drug Mounjaro—reduces alcohol intake as well as relapse-like behaviors in rats and mice. The findings

Tirzepatide may help lower the risk of diabetic retinopathy, a diabetes complication that can lead to vision loss. Douglas Sacha/Getty Images

Weight loss medications Mounjaro and Zepbound, which contain the

Hims & Hers said it pulled its controversial weight loss pill after discussions with “ecosystem stakeholders” during its fourth-quarter earnings call on Monday.

The comments come after Hims offered,

In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.

INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include

Shares in Novo Nordisk A/S took another battering after the company announced its next-generation obesity drug Cagrisema failed to show noninferiority to Eli Lilly and Co. Inc.’s Zepbound in an

MONDAY, Feb. 23, 2026 — People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2

MONDAY, Feb. 23, 2026 — Side effects like nausea or vomiting are common among folks taking Ozempic/Wegovy, but they’ll grin and bear it if they think they’re losing weight, a

Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the

Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday.

Patients in the

Pfizer has recently gone shopping for investigational GLP-1 drugs in China to take them to the rest of the world. Now, the large drugmaker is going to China and staying

Ecnoglutide, which Pfizer licensed from Sciwind Biosciences, is already approved in China for type 2 diabetes mellitus, and a marketing application for weight loss has been accepted by regulatory authorities

To understand what China’s fast-developing drug industry might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs.

At Roxborough Memorial Hospital in Philadelphia, surgeon Piotr Krecioch has his hands full launching a program offering surgical interventions to treat obesity. One in three Philadelphians are living with obesity,

People who lose weight with GLP-1 drugs are likely to continue using the medication despite the side effects. Image Credit: geckophotos/Getty Images

A recent study found that many people using

Could a simple patch, inspired by the weight-loss drug Ozempic, really help you shed excess kilos without the pain and effort of an injection?

By 2030, nearly half of all American adults will have obesity, according to research published in the New England Journal of Medicine. In every single state, researchers expect at least

Adding GLP-1 medications like Ozempic to progestin therapy could cut the risk of developing endometrial cancer. A retrospective study published in the journal JAMA Network Open found that women using

Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it.

(MedPage Today) — Note that some links may require registration or subscription.
FDA vaccine chief Vinay Prasad, MD, MPH, who made the controversial decision to refuse to review Moderna’s

Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.

Public Citizen contends that Novo Nordisk and Eli Lilly’s obesity drugs are straining budgets so much that generics should be authorized.

(MedPage Today) — Risk for a rare, potentially blinding eye condition was low, but it was significantly higher in diabetes patients who started semaglutide (Ozempic) versus SGLT2 inhibitors, an observational

Novo Nordisk is ramping up its footprint in Ireland with a planned expansion of its Athlone factory to make its Wegovy pill, the company confirmed to Endpoints News.

The

Viking Therapeutics Inc. said after-market hours Feb. 11 that it plans to advance its oral dual GLP-1/GIP receptor, VK-2735, into a phase III trial for obesity in the third quarter

A few weeks back, I moderated a dinner conversation among company heads of HR and benefits here in Denver organized by primary care operator Marathon Health.

These employee benefit

Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want

The oral version of Wegovy has made GLP-1 medicines more accessible and acceptable to many patients who had steered clear of injectable versions, healthcare analytics firm Truveta suggests.

(MedPage Today) — Women with nonmalignant uterine disease and a history of GLP-1 agonist and progestin treatment had a significantly lower risk of endometrial cancer (EC) compared with progestins alone,

Ascletis Pharma Inc. raised HK$843.53 million (US107.93 million) in a placement on the Hong Kong Stock Exchange to advance its lead program, ASC-30, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist

Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide (Victoza and Saxenda) can

TUESDAY, Feb. 10, 2026 — Lowering the annual cost of semaglutide by 18 percent (from $8,604 to $7,055) or making the current cash price available to all patients would make

Hims & Hers has withdrawn its low cost compounded weight loss pill after pressure from top U.S. health officials and a major lawsuit. Image courtesy of Novo Nordisk

Hims &

(MedPage Today) — The FDA approved three doses — 1.5 mg, 4 mg, and 9 mg — of a new oral semaglutide formulation for diabetes (Ozempic tablets), Novo Nordisk announced.<br

Novo Nordisk A/S’ television ad introducing the tablet form of its weight-loss drug, Wegovy (semaglutide), to American consumers didn’t pass regulatory muster.

With the use of GLP-1 medications on the rise, cardiologists are seeing benefits to heart health, and it might not all be related to weight loss alone. GLP-1 medications, including

Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.

MONDAY, Feb. 9, 2026 — Hims & Hers says it will stop selling a low-cost copy of a new weight-loss pill made by Novo Nordisk, after federal officials raised concerns

Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” in damages, John Kuckelman, the pharma’s general counsel, said. The wellness platform pulled its

Novo Nordisk on Monday said it is suing telehealth company Hims & Hers for allegedly infringing its patent on the weight loss medication semaglutide — not just for the pill

Novo Nordisk sues Hims & Hers for infringing on a key Wegovy patent.

GLP-1 drugs, which have helped some people curb drug and alcohol use, may unlock a pathway to moderation.

The telehealth company Hims & Hers said it will no longer sell a compounded version of Novo Nordisk’s Wegovy pill, just days after announcing the new product.

The move

GLP-1 drugs have ushered in a new era in weight loss.

Welcome back to another edition of Endpoints Weekly! It’s Super Bowl weekend with the Patriots and Seahawks fighting for the championship. While our many Boston-area readers are surely excited, most

FDA will take “decisive steps” to thwart companies from mass marketing unapproved, compounded versions of GLP-1 drugs

The US government said it will refer telehealth and GLP-1 company Hims & Hers to the Department of Justice for investigation, following the company’s controversial launch of a compounded version

A research team led by the Department of Medicine, under the School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has synergized the impacts

(MedPage Today) — As the Winter Olympic Games get underway, the World Anti-Doping Agency (WADA) is monitoring an unexpected class of drugs: GLP-1 receptor agonists.
An advisory group that

President Trump on Thursday night launched TrumpRx, the website he and his aides have touted as a platform aimed at lowering drug prices

And other biotech news brought to you by The Readout

Novo Nordisk has also spoken out strongly against Hims & Hers’ compounded Wegovy pill, with CEO Maziar Mike Doustdar telling investors the knockoff version is a waste of money.

I’ve been waiting for the big showdown between drugmakers and compounders for months, and it’s finally here.

Today on Post-Hoc Live at 12 p.m. ET, we’ll be talking about

Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test

FDA Commissioner Marty Makary took a not-so-subtle swipe at Hims & Hers in a social media post Thursday, saying his agency would “take swift action against companies mass-marketing illegal copycat

New GLP-1 ads, like telehealth provider Ro’s new campaign featuring tennis icon Serena Williams, aim to shift the conversation about weight loss drugs.

This year, the Super Bowl will feature

Novo Nordisk’s threatened legal action against Hims & Hers for selling a compounded version of the pharma giant’s newly launched Wegovy pill may be far from a slam-dunk win.

This week on “The Readout LOUD”: We discuss financial outlooks from Novo Nordisk and Eli Lilly, a closer look at why manufacturing problems have slowed the rollout of a crucial…

Hims & Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of “illegal…

(MedPage Today) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill semaglutide (Wegovy), just weeks after drugmaker Novo Nordisk launched

Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.

The Super Bowl is once again getting the GLP-1 ad treatment.

Hims & Hers is back with another combative spot that calls out the disparities in healthcare experiences between

Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.

One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.

What drug ads will air during Sunday’s Super Bowl? STATus Report host Alex Hogan and reporter at large Damian Garde have a rundown of what to expect.

Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular benefits for selected patients without diabetes who have established heart disease, but further price reductions are

In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and